95312-27-9

Basic information

• Product Name: methyl 5-(bromomethyl)isoxazole-3-carboxylate
• Synonyms: methyl 5-(bromomethyl)isoxazole-3-carboxylate;5-bromomethylisoxazole-3-carboxylic acid methyl ester;methyl 5-(bromomethyl)-1,2-oxazole-3-carboxylate;3-Isoxazolecarboxylic acid, 5-(bromomethyl)-, methyl ester
• CAS NO: 95312-27-9
• Molecular Formula: C₆H₆BrNO₃
• Molecular Weight: 220
• Mol File: 95312-27-9.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 5-(bromomethyl)isoxazole-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 5-(bromomethyl)isoxazole-3-carboxylate(95312-27-9)
• EPA Substance Registry System: methyl 5-(bromomethyl)isoxazole-3-carboxylate(95312-27-9)

Safety Data

• Hazardous Substances Data: 95312-27-9(Hazardous Substances Data)

Upstream product

• 19788-35-3 methyl 5-methylisoxazole-3-carboxylate 

Downstream Products

• 95312-11-1 5-(bromomethyl)-3-isoxazolecarboxylic acid 

Relevant articles and documents

EPOXYKETONE COMPOUNDS FOR ENZYME INHIBITION

The present disclosure relates to novel compounds and pharmaceutical compositions thereof which are useful as inhibitors of proteasomes. The compounds provided herein have improved proteasome potency and selectivity, and increased aqueous solubility, and

Hydroxypurine compound and use thereof

The invention discloses a hydroxypurine compound and a use of the hydroxypurine compound as a PDE2 or TNFa inhibitor and concretely discloses a compound shown in the formula (I) and its tautomer or pharmaceutically acceptable salt.

Compounds for enzyme inhibition

Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide

QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS

The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.